Expression profiles of glucocorticoid-inducible proteins in human papilloma virus-related oropharyngeal squamous cell carcinoma.
Annexin-A1
GILZ
SGK-1
glucocorticoids
human papilloma virus
oropharyngeal
squamous cell carcinoma
Journal
Frontiers in oral health
ISSN: 2673-4842
Titre abrégé: Front Oral Health
Pays: Switzerland
ID NLM: 9918227262706676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
08
2023
accepted:
11
10
2023
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Human papillomavirus virus-related oropharyngeal squamous cell carcinoma (HPV-OPSCC) comprises a significant portion of head and neck cancers. Several glucocorticoid-inducible proteins play important roles in pathogenesis of some cancers but their status and roles in HPV-OPSCC remain elusive; these include the glucocorticoid-induced leucine zipper (GILZ), Annexin-A1 and serum glucocorticoid-regulated kinase-1 (SGK-1). We determined expression profiles of these proteins, using immunohistochemistry, in archived biopsy samples of patients diagnosed with HPV-OPSCC; samples of non-cancer oral lesions (e.g., hyperkeratosis) were used as controls. GILZ staining was primarily confined to nuclei of all tissues but, in HPV-OPSCC specimens, neoplastic cells exhibiting mitosis displayed prominent cytoplasmic GILZ expression. On the other hand, nuclear, cytoplasmic and membranous Annexin-A1 staining was observed in suprabasal cell layers of control specimens. A noted feature of the HPV-OPSCC specimens was few clusters of matured and differentiated nonbasaloid cells that showed prominent nuclear and cytoplasmic Annexin-A1 staining while the remainder of the tumor mass was devoid of staining. Cytoplasmic and nuclear staining for SGK-1 was prominent for control than PV-OPSCC specimens while staining for phosphorylated SGK-1 (pSGK-1; active) was prominent for cell membrane and cytoplasm of control specimens but HPV-OPSCC specimens showed mild and patchy nuclear and cytoplasmic staining. Semi-quantitative analysis of GILZ immunostaining indicated increased staining area but similar normalized staining for HPV-OPSCC compared to control specimens. By contrast, staining area and normalized staining were reduced for other proteins in HPV-OPSCC than control specimens. Our collective observations suggest differential cellular localization and expression of glucocorticoid-inducible proteins in HPV-OPSCC suggestive of different functional roles in pathogenesis of this condition.
Identifiants
pubmed: 37954869
doi: 10.3389/froh.2023.1285139
pmc: PMC10634427
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1285139Informations de copyright
© 2023 Mozaffari, Abdelsayed, Emami and Kavuri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Cancer Immunol Immunother. 2016 Apr;65(4):393-403
pubmed: 26899388
Cells. 2021 Dec 30;11(1):
pubmed: 35011684
Cells. 2021 Dec 05;10(12):
pubmed: 34943928
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
J Clin Invest. 2007 Jun;117(6):1605-15
pubmed: 17492054
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41
pubmed: 24794262
J Biol Chem. 2001 May 18;276(20):16649-54
pubmed: 11278764
Eur J Cancer. 2020 Jul;134:52-59
pubmed: 32460181
Oral Oncol. 2017 Feb;65:23-32
pubmed: 28109464
J Exp Clin Cancer Res. 2012 Jan 12;31:4
pubmed: 22240294
Cells. 2021 Mar 15;10(3):
pubmed: 33804148
Biochem J. 2013 Jun 15;452(3):499-508
pubmed: 23581296
Front Oncol. 2020 Dec 21;10:545385
pubmed: 33425717
BMC Cancer. 2020 Feb 27;20(1):161
pubmed: 32106831
Mol Cancer. 2009 Oct 08;8:83
pubmed: 19814803
Cell Physiol Biochem. 2017;43(3):1301-1308
pubmed: 28992614
Cell Death Differ. 2015 Jan;22(1):118-30
pubmed: 25168242
Cell Death Dis. 2018 Feb 21;9(3):305
pubmed: 29467389
Front Oncol. 2021 Jan 19;10:608722
pubmed: 33542904
J Proteome Res. 2014 Feb 7;13(2):1002-11
pubmed: 24405156
J Pharmacol Exp Ther. 2020 Dec;375(3):398-405
pubmed: 33008869
Am J Rhinol. 2005 Sep-Oct;19(5):483-7
pubmed: 16270603
Bio Protoc. 2019 Dec 20;9(24):
pubmed: 31867411
Trends Mol Med. 2019 Apr;25(4):315-327
pubmed: 30871809
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Am J Hypertens. 2014 Jun;27(6):846-56
pubmed: 24429675
Cell Death Dis. 2018 Apr 26;9(5):463
pubmed: 29695779
Oncogene. 2011 Jul 14;30(28):3198-206
pubmed: 21478911
J Oral Pathol Med. 2009 Apr;38(4):362-70
pubmed: 18673418
Oncotarget. 2015 Mar 30;6(9):6931-43
pubmed: 25749387
Cancer Gene Ther. 2011 Aug;18(8):563-70
pubmed: 21546924
J Chemother. 2020 Sep;32(5):263-267
pubmed: 32067575
J Biol Chem. 2012 Jan 6;287(2):1242-51
pubmed: 22110132
Sci Rep. 2016 Jul 28;6:30405
pubmed: 27465291
PLoS One. 2014 Dec 08;9(12):e113795
pubmed: 25485633
Nat Rev Clin Oncol. 2022 May;19(5):306-327
pubmed: 35105976
Cell Physiol Biochem. 2015;35(5):2006-18
pubmed: 25871776
Horm Cancer. 2014 Apr;5(2):72-89
pubmed: 24615402
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Int J Oncol. 2012 Nov;41(5):1751-61
pubmed: 22923130
Am J Pathol. 2004 Jan;164(1):73-9
pubmed: 14695321
Breast Cancer Res Treat. 2012 Sep;135(2):469-79
pubmed: 22842983
J Cell Sci. 2019 Apr 9;132(7):
pubmed: 30837283
Virology. 2016 Sep;496:35-41
pubmed: 27240147
J Mol Med (Berl). 2009 Dec;87(12):1221-39
pubmed: 19756449
Acta Pharm Sin B. 2018 Sep;8(5):767-771
pubmed: 30245963
Ther Adv Med Oncol. 2020 Jul 15;12:1758835920940946
pubmed: 32728395
Gynecol Oncol. 2015 Sep;138(3):656-62
pubmed: 26115975
Oral Dis. 2018 Mar;24(1-2):224-227
pubmed: 29480615
Front Oral Health. 2021 Sep 16;2:675288
pubmed: 35048019
Oncotarget. 2015 Nov 10;6(35):37511-25
pubmed: 26462020
Tumour Biol. 2016 Mar;37(3):3017-24
pubmed: 26419593